in Nord-Tr ø ndelag County, Norway. All residents of the county from 20 years of age were invited. The study included 29,610 individuals (61 % response rate) who reported whether they had heartburn or acid regurgitation. The association between tobacco smoking cessation and improvement in GERS was assessed by logistic regression, providing odds ratios (ORs) with 95 % confi dence intervals (CIs). The analyses were stratifi ed by antirefl ux medication, and the results were adjusted for sex, age, body mass index (BMI), alcohol consumption, education, and physical exercise. Subgroup analyses were also stratifi ed by BMI.
INTRODUCTION
Tobacco smoking is associated with an increased risk of gastroesophageal refl ux symptoms (GERS) according to several population-based studies from Western countries ( 1 -9 ) . Th e odds ratios (ORs) of GERS among smokers compared with non-smokers have been in the range of 1.3 -2.5. Tobacco smoking increases the risk of GERS by reducing the lower esophageal sphincter pressure, facilitating gastric acid to reach the esophagus ( 10 -12 ) , and reducing the salivary bicarbonate secretion, which neutralizes the acidity of the gastric contents ( 13, 14 ) . In addition, both GERS and tobacco smoking are independently associated with an increased risk of adenocarcinoma of the esophagus and esophagogastric junction ( 15 -19 ) . Two recent reviews on the eff ect of lifestyle changes on gastroesophageal refl ux disease (GERD) concluded that the evidence to date does not support an improvement in GERD aft er cessation of tobacco use ( 20, 21 ) . However, in the available studies, only the very short-term eff ect of smoking cessation on GERD outcomes was evaluated ( 22 -24 ) . Our hypothesis states that tobacco smoking cessation improves GERS. Th e aim of this study was to clarify if there is an association between tobacco smoking cessation and improvement in GERS in a large and population-based study with long follow-up.
METHODS

Study design, setting, and participants
Th e study was based on a large population-based health study, the Nord-Tr ø ndelag health study (the HUNT study), which we have used previously for epidemiological studies of GERS ( 6,25 -27 ) . Th e HUNT study is based on a series of health surveys where the entire population of Nord-Tr ø ndelag County, Norway, from 20 years of age has been invited to participate. Th e fi rst survey was conducted in 1984 -1986 (HUNT 1), the second survey in 1995 -1997 (HUNT 2), and the third survey in -2008 . In all surveys a basic questionnaire was accompanying the invitation letter and the participants were asked to meet at screening stations for clinical and laboratory examinations. A short questionnaire (Mini-Q) was sent to non-participants aft er HUNT 3 in 2009 and those who responded to the Mini-Q were also included in our study. Th e questionnaires and examinations included a wide range of health-related topics ( 28 ) .
Assessment of the outcome GERS
In HUNT 2 and HUNT 3 / Mini-Q, GERS status of the participants was defi ned based on the participants ' response to the following question: " To what degree have you had heartburn or acid regurgitation during the previous 12 months? " Th e question had three response alternatives: " No complaints, " " Minor complaints, " or " Severe complaints. " Improvement in GERS status from severe GERS in HUNT 2 to no or minor GERS in HUNT 3 / Mini-Q was defi ned as the study outcome, whereas severe GERS at both time points (stable GERS) were defi ned as reference. We have previously validated this GERS question and found that 25 -31 % of those reporting minor GERS and 95 -98 % of those reporting severe GERS had at least weekly complaints ( 25 ) . Th is suggests that the majority of those reporting severe GERS actually have GERD according to the Montreal defi nition and classifi cation of GERD ( 25, 26, 29 ) .
Assessment of the exposure tobacco smoking
In HUNT 2, the participants were asked about their tobacco smoking status by answering yes or no to these questions: " Have you ever smoked daily?, " " Do you smoke cigarettes daily?, " " Do you smoke cigars or cigarillos daily?, " and " Do you smoke pipe daily? " In HUNT 3 / Mini-Q, the participants were asked: " Do you smoke? " Th e response alternatives to this question were: " No, I have never smoked, " " No, I have quit smoking, " " Yes, cigarettes occasionally (parties / vacation, not daily), " or " Yes, cigarettes daily. " Th ose who quitted daily tobacco smoking or reduced daily smoking to only occasional smoking between HUNT 2 and HUNT 3 / Mini-Q were defi ned as " exposed " to tobacco smoking cessation, and those who were persistent daily tobacco smokers at both time points were regarded as " unexposed " to such cessation.
Assessment of covariables
Covariables were selected based on their known association with GERS: sex, age, alcohol consumption, education, physical exercise, body mass index (BMI), and antirefl ux medication. Data on sex and age at participation were recorded at each survey. Average frequency of alcohol consumption and physical exercise was reported through questionnaires in HUNT 3 / Mini-Q. Years of education were reported through questionnaires in HUNT 2. BMI was assessed by objectively measuring height and body weight under standardized conditions and by trained personnel at the screening stations in HUNT 2 and HUNT 3, whereas in Mini-Q height and weight were reported by the responders. BMI was calculated as body weight in kilograms divided by the square height in meters (kg / m 2 ). Antirefl ux medication included proton pump inhibitors, histamine-2-receptor antagonists, and antacids. In Norway, the prescription rules have until 2010 demanded a prescription from a physician to get proton pump inhibitors or histamine-2-receptor antagonists, except small packages of lowdose histamine-2-receptor antagonists that have been available over the counter. In this study, information was gathered on the participants ' use of prescribed antirefl ux medication through the Norwegian Prescription Database (NorPD). Th e NorPD was established in 2004, and all prescribed medications from all Norwegian pharmacies were by legislation reported to the NorPD. From the NorPD data, the average use of prescribed antirefl ux medication was estimated based on the number of tablets prescribed during the HUNT 3 data collection period (2006 -2008) . In addition, the questionnaires in HUNT 3 included an assessment of over the counter medication use against several complaints, including heartburn or acid regurgitation. Th e question was: " How oft en have you used over the counter medication against the following complaints during the last month? " Th e participants responded with one of four alternatives to this question: " Rare / never, " " 1 -3 times / week, " " 4 -6 times / week, " or " Daily. " Th us, the two data sources were complementary with regard to the use of antirefl ux medication. Th ere was no information on antirefl ux medication available during the HUNT 2 period.
Statistical analysis
Response rates were calculated from those eligible to participate at each survey, excluding those who were no longer residents in the county or had died. Th e association between tobacco smoking cessation (exposure) and GERS status (outcome) was assessed by multivariable logistic regression. Based on acknowledged criteria of a confounding factor, antirefl ux medication should not be included in the regression model, but instead be assessed as an eff ect modifi er ( 30 ) . To account for the eff ect of antirefl ux medication on GERS, the analyses were stratifi ed by the use of antirefl ux medication, no or less than weekly use or at least weekly use, and the results were reported for each stratum separately. Participants with missing information on antirefl ux medication were analyzed as using no or less than weekly antirefl ux medication, because in the NorPD data it was not possible to distinguish between those with truly missing data and those who did not receive a prescription. Secondary analyses were also stratifi ed by BMI using ESOPHAGUS Tobacco Smoking and Gastroesophageal Reflux the categories defi ned by the World Health Organization: < 18.5 (underweight), 18.5 -24.9 (normal weight), 25.0 -29.9 (preobese), and ≥ 30.0 (obese) ( 31 ) . To account for other potential confounders of the association between tobacco smoking and GERS, a continuous variable for age and categorical variables for sex, alcohol consumption ( < weekly or ≥ weekly), education ( ≤ 12 years or > 12 years), and physical exercise ( < weekly or ≥ weekly) were included in the regression model. Th e statistical analyses were performed using Stata / IC 12.1 by StataCorp LP (College Station, TX).
Study approval
Th e study was approved by the Regional Committee for Medical and Health Research Ethics, Central-Norway (ID 4.2009.328).
RESULTS
Participants
We have previously published a complete fl owchart of the participants ( 26 ) . In HUNT 2 and HUNT 3 / Mini-Q, 58,869 individuals (64 % response rate) and 44,997 individuals (49 % ) reported GERS status, respectively. Among these, the 29,610 individuals (61 % ) who reported GERS status at both time points were eligible. Th e average follow-up time was approximately 11 years. Among the 1553 participants with severe GERS (5 % ) in HUNT 2, the 486 (31 % ) who were daily tobacco smokers were included in the present study. Of these participants, 182 quitted smoking and 31 reduced to occasional smoking. In total, 213 (44 % ) were previous daily smokers, whereas 251 (52 % ) were persistent daily smokers in HUNT 3 / Mini-Q. In both these groups, about 60 % were using antirefl ux medication at least weekly ( Figure 1 ). Th e mean BMI was similar between the groups, but obesity was less common among the persistent daily smokers. Compared with the previous daily smokers, the persistent daily smokers were characterized by higher female representation, lower mean age, lower education, lower level of physical exercise, and lower alcohol consumption ( Table 1 ) .
Associations
Among the daily tobacco smokers with severe GERS in HUNT 2 using no or less than weekly antirefl ux medication, there was no statistically signifi cant association between tobacco smoking cessation and GERS status (adjusted OR 0.95; 95 % CI: 0.39 -2.30) compared with persistent daily smoking ( Table 2 ). However, among the daily tobacco smokers with severe GERS in HUNT 2 using at least weekly antirefl ux medication, tobacco smoking cessation was associated with an improvement in GERS status from severe to no or minor complaints (adjusted OR 1.78; 95 % CI: 1.07 -2.97) compared with persistent daily smoking ( Table 2 ) . Secondary, subgroup analyses found that the association only was present among individuals within the normal weight range ( Table 3 and Figure 2 ). Th ere was no association between tobacco smoking cessation and GERS status among individuals with minor GERS in HUNT 2 (data not shown).
DISCUSSION
Th is study found that tobacco smoking cessation was associated with an improvement in severe GERS among normal weight individuals using antirefl ux medication at least weekly. Th ere was, however, no such pattern in individuals with minor GERS, overweight, or those using antirefl ux medication less than weekly.
Strengths of this study include the population-based design, reducing selection bias, and increasing generalizability compared with clinic-based studies. Except for slightly lower average income and education and lack of a large city, the population of NordTr ø ndelag County is representative of the Norwegian population at large ( 28, 32 ) . In addition, the prospective design circumvents recall bias and the wide range of variables assessed, including antirefl ux medication, makes adjustments for relevant confounders possible. Limitations include the inherent arbitrary defi nition of GERD, reducing the accuracy of identifying individuals with true GERD, probably leading to some misclassifi cation. Misclassifi cation is also possible among the exposure and covariables, as the variables were dichotomized. In addition, the associations found were only modest and residual confounding can never be totally excluded in observational research. Loss to follow-up may introduce selection and survival bias, but such potential biases are probably small as Participants with no information on antirefl ux medication were included in never or less than weekly category. a Antirefl ux medication: proton pump inhibitors, histamine-2-receptor antagonists, and antacids; participants with no information on antirefl ux medication were included in never or < weekly category. 
ESOPHAGUS
Tobacco Smoking and Gastroesophageal Reflux the general population. As this is an observational study, a causal relationship cannot be claimed, and we do not know if smoking cessation occurred before improvement of GERS or the other way around. However, the results are consistent with the pathophysiology ( 10 -14 ) and a randomized controlled trial of smoking cessation would be very hard and unethical to perform. Th e study only considered frequency of tobacco smoking, not dose or time since cessation. However, pathophysiologic data suggests that the eff ect of tobacco smoking is very short lived, and thus dose and time since cessation should be of less importance. In addition, daily smoking is a common cutoff level in observational study, making comparisons with other studies easier. We found no association between tobacco smoking cessation and improvement in minor GERS. Th is probably refl ects the heterogenetic nature of individuals reporting minor GERS, including individuals with functional syndromes. Th ese syndromes have other pathophysiological mechanisms, at least partly not related to gastroesophageal refl ux or tobacco smoking. Owing to the low absolute number of individuals, we defi ned the " exposure " in this study to be a combination of those quitting smoking and those only reducing daily smoking to occasional smoking. Even so, we found an association between the " exposure, " i.e., reduced a previous publication has shown that there was virtually no difference in the distribution of the study variables between all the HUNT 2 participants ( N = 58,869) and the cohort who was followed up from HUNT 2 to HUNT 3 / Mini-Q ( N = 29,610) ( 27 ) . Owing to the observational design, causal relationships cannot be claimed. As there were low numbers of missing data among the participants ( Table 1 ) , complete case analyses were performed. Th e three previous studies addressing smoking cessation and GERD found confl icting results. One study found no infl uence of 24 h refrainment from smoking on 24-h pH measurements of the distal esophagus in 10 smokers with GERS ( 22 ) . Another study found no immediate eff ect of smoking cessation on total esophageal acid exposure in eight smoking men with moderateto-severe endoscopic evidence of GERD ( 23 ) . Th e third study, however, found a reduced distal esophageal acid exposure in 14 smokers with refl ux esophagitis who abstained from smoking for 48 h ( 24 ) . Our study is the fi rst epidemiological investigation testing whether tobacco smoking cessation improves GERS and the fi rst study that evaluates such cessation in a long-term perspective.
Th e results of our study suggest that tobacco smoking cessation may improve severe GERS among normal weight individuals in tobacco smoking, and the outcome, i.e., improved GERS. Th is suggests that total smoking cessation would increase the chance of success even more than apparent from our study. Th e improvement in GERS was limited to persons of normal weight using at least weekly antirefl ux medication. Th e lack of improvement in overweight individuals might be explained by the strong association between BMI and GERS, which might dominate compared with the eff ect of tobacco smoking on GERS in overweight individuals. Th us, the pathophysiology of GERS is probably driven by the weight in overweight and obese individuals and smoking has a minor role, but in individuals of normal weight smoking has a more important role in the pathophysiology. Th e lack of improvement among those using no or less than weekly antirefl ux medication suggests that the individuals with severe GERS have an advanced stage of GERD, i.e., esophagitis or symptoms related to the presence of hiatal hernia, which does not resolve only with tobacco smoking cessation. However, weight loss and tobacco smoking cessation might reduce the need for antirefl ux medication over time. In addition, these lifestyle measures are also advisable owing to the eff ects on general health. As tobacco smoking as well as GERS is associated with adenocarcinoma of the distal esophagus and gastric cardia, persons with GERS should be advised to refrain from smoking ( 16 -19 ) . Th e population-based design argues for generalizability to the general Norwegian population and other Western populations of mainly Caucasians.
In conclusion, although tobacco smoking cessation was not associated with any decrease in GERS among individuals with minor GERS, overweight, or those using antireflux medication less than weekly, an improvement in severe GERS was identified among normal weight individuals using regular antireflux medication. Tobacco smoking cessation might be beneficial in this latter group of patients suffering from gastroesophageal reflux.
3 This study suggests that tobacco smoking cessation might be benefi cial in normal weight patients suffering from gastroesophageal refl ux. Odds ratio and 95 % confi dence interval (CI) of improvement in severe gastroesophageal refl ux symptoms by tobacco smoking cessation, comparing previous daily tobacco smokers with persistent daily tobacco smokers as reference. Restricted to those using at least weekly antirefl ux medication and stratifi ed by body mass index (BMI). Model adjusted for sex, age, alcohol consumption, education, and physical exercise.
